Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist
Sponsor: AstraZeneca
Summary
This Phase II study is a randomized, parallel group, double blinded, placebo-controlled, multicenter to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and type 2 diabetes on stable GLP-1 RA therapy.
Official title: A Phase II Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
69
Start Date
2025-03-12
Completion Date
2026-05-27
Last Updated
2026-03-03
Healthy Volunteers
Yes
Conditions
Interventions
AZD6234
Weekly SC injections of AZD6234
Placebo to match
Weekly SC injections of matching placebo
Locations (18)
Research Site
Birmingham, Alabama, United States
Research Site
Mobile, Alabama, United States
Research Site
Doral, Florida, United States
Research Site
Jacksonville, Florida, United States
Research Site
Miami, Florida, United States
Research Site
Miami, Florida, United States
Research Site
Winter Park, Florida, United States
Research Site
Canton, Georgia, United States
Research Site
Fayetteville, Georgia, United States
Research Site
Chicago, Illinois, United States
Research Site
Oak Brook, Illinois, United States
Research Site
Newton, Kansas, United States
Research Site
Lexington, Kentucky, United States
Research Site
Kansas City, Missouri, United States
Research Site
Las Vegas, Nevada, United States
Research Site
Norman, Oklahoma, United States
Research Site
Knoxville, Tennessee, United States
Research Site
San Antonio, Texas, United States